Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Dose-Ranging and Interception Study of Linvoseltamab in Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

NCT06140524 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT06140524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06140524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Dose-Ranging and Interception Study of Linvoseltamab in Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 2
Overall status
Recruiting
Start date
September 16, 2024
Completion date
May 18, 2032
Enrollment
116 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

monoclonal gammopathy of undetermined significance (mgus), smoldering multiple myeloma (smm)